Skip to content
FibonacciAestheticsLog inTry it free

Clinical work and records

How to document a filler vascular occlusion: what to write, when, and what the sources say

Filler vascular occlusion: what to document in the chart, hour by hour (signs, product, batch, area, hyaluronidase), with the clinical and legal sources.

The Fibonacci editorial teamUpdated on 9 min read

Medical supplies ready in an orange tray
In this article
  1. Why you write as it happens
  2. What you write: the list
  3. Reporting to the manufacturer and the authority
  4. Follow-up in the days after
  5. A model line

When you suspect a vascular occlusion from filler, the chart must be able to state four things: what you injected (product and batch), where, what signs you saw and at what time, and what you did next, with the times. The first two you already have in the treatment line. The other two are written as it happens, or immediately afterwards, because time is the part of the story that nobody reconstructs well from memory.

This sets out what to record and why, with the clinical sources. It does not give treatment indications and does not indicate doses: what is done in the face of an occlusion is decided by your protocol and your judgement. Here we are talking about paperwork.

Why you write as it happens

A review of complications of minimally invasive aesthetic procedures recalls that suspected occlusion arises in the face of extreme pain, blanching or mottling of the skin, and that the complication must be treated as an emergency to give some chance of full recovery (PMC3461789 (opens in a new tab)). So, at that moment, your hands are busy. The record is not the priority. It remains true, however, that if someone later disputes how things went, the answer lies in three numbers: the time the first sign appeared, the time you acted, and the time the patient was reassessed. Flag it immediately, even on a sheet of paper, and transcribe it as soon as you can.

In Emergency mode the clock starts on opening, the steps of your protocol are ticked off as you carry them out, and the record shows the times at which you marked each step, not times reconstructed afterwards (outcomes, complications and emergencies). The start instant and the ticked steps are saved in the browser before any call to the server: if the network drops, the record is not lost. The screen does not suggest drugs, doses or diagnoses: the protocol is your own text, shown as it is.

What you write: the list

1. Product, batch, area

Product and batch, as in every session (how to write the treatment line). Here they are needed twice over: for the chart and for any report, because the batch is the datum by which the manufacturer identifies the product. Add the injection points and the amount per point.

If something unusual happened during the injection, write it down as a fact. In the clinical case we use as an example, the patient had received filler to the face and chin and the doctor had stopped the injection at the midpoint because he had met resistance and caused immediate discomfort (PMC12806579 (opens in a new tab)). It is the kind of detail that gets lost if you do not write it that day.

2. The timeline

The case cited is written as a timeline, and that is the most useful form for the chart. The procedure is time zero. At 6 hours tension appears, at 24 hours increasing pain, mottled discolouration (livedo reticularis) and capillary refill time greater than 2 seconds, and hyaluronidase is started at 25 hours, with every subsequent administration recorded with its time and its amount.

Translated into chart lines, for each event:

  • exact time (or the best estimate, declared as such);
  • what was seen or reported;
  • what was done, by whom;
  • who was called and at what time.

3. The signs observed

The number of signs to record depends on where they present. A multicentre study of 100 patients with a filler vascular event, assessed with Doppler ultrasound, included cases with a clinical diagnosis based on signs such as pain out of proportion to the procedure, delayed capillary refill time, blanching, livedo reticularis, pustules, ecchymosis, coagulative necrosis or eschar, distributed according to the arterial territories of the face. In the group, livedo was the most frequent sign (46%), then blanching (38%) and pain (25%) (Sigrist et al., 2026 (opens in a new tab)). In the chart, for each sign write: present or absent, where (with the side), when you saw it.

If the patient reports visual disturbance, the article on vision loss devotes a paragraph to "recognition and documentation" (PMC13002150 (opens in a new tab)). It describes the sudden and profound onset of vision loss, sometimes with ocular pain, nausea, vomiting and dizziness, and proposes a list to be completed for the left and right eye: visual acuity with simple bedside methods (finger counting, hand movement, light perception, because the Snellen chart requires a distance that is often not available in the clinic), direct and consensual pupillary reflex, ocular motility in the four directions of gaze with an indication of pain on movement, and on the skin the presence of blanching or livedo in the territories of the supratrochlear, supraorbital and dorsal nasal arteries. It is a list of what is looked at and noted, and the same source warns that any delay in starting treatment must be avoided: the list is completed quickly, it is not postponed.

4. What was done, and with which product

For hyaluronidase, when it was used, a clinical consultation sheet recalls that the injection site must be documented and that, if the affected area is visible, its borders can be marked to follow its change (section "Monitoring", where the discussion concerns extravasation; StatPearls (opens in a new tab)). The record must therefore include: product, batch (of the hyaluronidase too), amount per administration, site and time. Why the exact amount: in the Doppler study the doses of hyaluronidase administered "varied widely" from one patient to another. Without the number, the chart does not allow you to know what was given.

Record the other measures too: drugs, compresses, supportive measures. Fibonacci's complication form has the fields "What you observed" and "What you did", with examples that include hyaluronidase, compresses and antibiotic.

5. Imaging examinations

If ultrasound or Doppler are used, the review on ultrasound-guided hyaluronidase injections (PMC12586333 (opens in a new tab)) explains that the complication can arise from three mechanisms (direct injection of filler into an artery, compression of the vessel by excess filler, arterial spasm) and that ultrasound serves to visualise the filler deposits and flow alterations. For the chart, imaging is a document: save the image or the report with date, time, who performed it and what it shows, and link it to the event. An image that exists only on the ultrasound device is not in the chart.

6. Referral and communication with the patient

If you refer the patient to a centre, note to whom, at what time, by what means and what you transmitted. The article on vision loss describes the organisation of the referral (the assistant calls the ambulance and, in agreement with the doctor, the on-call doctor of the receiving hospital) and insists on coordination between services. It is enough that it remains written down who called whom.

Then write down what you told the patient. Italian Law 219/2017, article 1 (opens in a new tab), paragraph 3, gives every person the right to know their own state of health. In Annex IV of implementing regulation 2022/2346 for fillers, the manufacturer also provides that the instructions recommend to the user a period of monitoring after administration and that the consumer receives before treatment a sheet with the residual risks, information on when to contact a healthcare professional and on how to report adverse effects to the manufacturer, with a part intended to record the site, number and volume of injections (EUR-Lex (opens in a new tab)). If you handed it over, write that down.

Reporting to the manufacturer and the authority

Italian Legislative Decree 137/2022, article 10 (opens in a new tab), states that healthcare professionals, public or private, who detect a serious incident with a medical device, even merely suspected, are required to communicate it to the Ministry of Health, within the terms and in the manner established by ministerial decrees (paragraph 2). The communication must also be sent to the manufacturer or its authorised representative, including through the distributor (paragraph 5). Omission is punishable by an administrative penalty of 26,000 to 120,000 euros (article 27, paragraph 45).

Two warnings. The first: the precise terms are in the ministerial decree in force: check it on the Ministry of Health portal. The second: the legislative decree speaks of "medical device". Annex XVI fillers are products without a medical purpose to which regulation 2017/745 applies as to devices from the date of application of the common specifications (22 June 2023, regulation 2022/2346): if your product has the transitional period or the marking, that is a question for the supplier. It is discussed in the article on the obligations of those who use a medical device.

Alongside each recorded complication, the program prepares the text to be copied into the ministry form and opens a reminder with the deadline derived from the severity you have chosen. It transmits nothing, does not decide whether the incident is serious and does not enter the patient's data (the form receives the event and the product, never the person). Recording a complication in the program is not equivalent to a pharmacovigilance report.

Follow-up in the days after

The event does not close with the visit. If you follow the patient up in the following days, each check has its own line with date, time and signs (the same list as the first time, so they can be compared). In the clinical case cited the pain had resolved by the third day, the colour markedly improved by the fourteenth and full recovery by the twenty-first: these are three dates that, in the chart, count as three lines. The article on follow-up after treatment develops the follow-up record. For photographs of the skin sign, what is said about photos in the chart applies.

A model line

Example with fictitious data, for form only.

TimeWhatWho
T0 (10:30)End of injection, point 3 right, resistance feltDoctor
T0 + a few hoursPatient telephones: tension in the areaReception, reported to the doctor
T0 + 24 hVisit: signs observed with the list (presence/absence, side)Doctor
Immediately afterMeasures and amount for each administration, with batch and timeDoctor
Immediately afterCall to the centre, name and time, what was transmittedDoctor or assistant
Within the termsReport to the manufacturer and the MinistryDoctor

The guide after a complication brings the same steps together, with the notice to the insurer; the page on the incomplete chart explains why a gap weighs heavily.

What Fibonacci does for this

This is how it looks in Fibonacci, with sample data:

Sessions with product and batch in Fibonacci, with sample data

Sources

  1. Vascular Occlusion Following Low-volume Chin Filler (PMC12806579) (opens in a new tab)
  2. Management of Visual Loss Following Hyaluronic Acid Filler Injections (PMC13002150) (opens in a new tab)
  3. Ultrasound-Guided Hyaluronidase Injections for Filler-Induced Arterial Ischemia (PMC12586333) (opens in a new tab)
  4. Doppler Ultrasound Findings in Filler-Related Facial Vascular Adverse Events (PMC13256399) (opens in a new tab)
  5. StatPearls, Hyaluronidase (NBK545163) (opens in a new tab)
  6. Complications of Minimally Invasive Cosmetic Procedures: Prevention and Management (PMC3461789) (opens in a new tab)
  7. Italian Legislative Decree 5 September 2022, no. 137, arts. 10 and 27 (Normattiva) (opens in a new tab)
  8. Commission Implementing Regulation (EU) 2022/2346, Annex IV (EUR-Lex) (opens in a new tab)
  9. Commission Implementing Regulation (EU) 2022/2346, recitals and Article 3 (EUR-Lex) (opens in a new tab)
  10. Italian Law 22 December 2017, no. 219, art. 1 (Normattiva) (opens in a new tab)

These articles explain what regulations and guidelines require and what is documented in the medical record. They are not legal or tax advice on your situation and do not say how to treat a patient.

Try Fibonacci in your practice for 15 days, no credit card needed

Within one working day we call you: together we set up your practice and import your data.

Try it free

Read next

All articles